Bullish option flow detected in Crispr Therapeutics with 1,861 calls trading, 1.2x expected, and implied vol increasing over 1 point to 53.61%. Jan-25 50 calls and Sep-24 40 puts are the most active options, with total volume in those strikes near 470 contracts. The Put/Call Ratio is 0.28. Earnings are expected on November 4th.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Oruka announces closing of merger with ARCA Biopharma
- Crispr Therapeutics call volume above normal and directionally bullish
- Crispr Therapeutics price target lowered to $100 from $120 at Truist
- Mid-Cap Stocks: CRSP Offers Tremendous Growth Potential With Inherent Risks
- Crispr Therapeutics price target lowered to $60 from $66 at RBC Capital